Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Atomo Diagnostics Ltd. ( (AU:AT1) ) is now available.
Atomo Diagnostics Limited has successfully completed its Share Purchase Plan (SPP), raising $272,387.50 through applications for 14,723,685 shares, with an additional Tranche 2 Placement approved to raise $1,257,800. This fundraising initiative strengthens the company’s financial position, enabling it to advance its operational activities and maintain its competitive edge in the global diagnostic market.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that supplies unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company’s patented devices simplify testing procedures, enhance usability, and improve reliability for rapid point-of-care and at-home testing applications. Atomo has commercialized several products internationally and has supply agreements for testing applications targeting infectious diseases such as HIV, Active Syphilis, viral vs bacterial differentiation, and early pregnancy detection.
Average Trading Volume: 610,084
Technical Sentiment Signal: Sell
Current Market Cap: A$10.29M
For detailed information about AT1 stock, go to TipRanks’ Stock Analysis page.